Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins

Leukemia

Volumn 26, Issue 7, 2012, Pages 1663-1670

  Schoenhals, M ^a   Frecha, C ^b,c,d   Bruyer, A ^a   Caraux, A ^a   Veyrune, J L ^e   Jourdan, M ^a   Moreaux, J ^a,e   Cosset, F L ^b,c,d   Verhoeyen, E ^b,c,d   Klein, B ^a,e,f  

^a HÔPITAL SAINT ELOI   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f UNIV MONTPELLIER   (France)

Author keywords

measles glycoproteins; multiple myeloma; plasma cell; transduction

Indexed keywords

CD150 ANTIGEN; HYBRID PROTEIN; LENTIVIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; VIRUS HEMAGGLUTININ;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MEASLES VIRUS; MULTIPLE MYELOMA; MYELOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN;

ANTIGENS, CD; ANTIGENS, CD46; CELLS, CULTURED; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; LENTIVIRUS; MEASLES VIRUS; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, CELL SURFACE; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

EID: 84863775773     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.36     Document Type: Article

References (34)

1. Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med 2011; 62: 249-264.
2. Yoshida T, Mei H, Dörner T, Hiepe F, Radbruch A, Fillatreau S et al. Memory B and memory plasma cells. Immunol Rev 2010; 237: 117-139.
3. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematol Am Soc Hematol Educ Program 2005; 2005: 346-352.
4. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton III LJ. Longterm follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic Series 25 years later. Mayo Clin Proc 2004; 79: 859-866.
5. Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res 2011; 17: 1234-1242.
6. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev 2011; 25: 107-112.
7. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D et al. A highrisk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96: 574-582.
8. De Vos J, Bagnis C, Bonnafoux L, Requirand G, Jourdan M, Imbert MC et al. Comparison of murine leukemia virus, human immunodeficiency virus, and adeno-associated virus vectors for gene transfer in multiple myeloma: lentiviral vectors demonstrate a striking capacity to transduce low-proliferating primary tumor cells. Hum Gene Ther 2003; 14: 1727-1739.
9. Frecha C, Costa C, Levy C, Negre D, Russell SJ, Maisner A et al. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 2009; 114: 3173-3180.
10. Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, Cosset FL et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008; 112: 4843-4852.
11. Hummel HD, Kuntz G, Russell SJ, Nakamura T, Greiner A, Einsele H et al. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. J Gen Virol 2009; 90: 693-701.
12. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009; 11: 43-53.
13. Stief AE, McCart JA. Oncolytic virotherapy for multiple myeloma. Expert Opin Biol Ther 2008; 8: 463-473.
14. Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, Redal N et al. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw 2005; 16: 57-64.
15. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A et al. Proliferation is a central independent prognostic factor and target for personalized and riskadapted treatment in multiple myeloma. Haematologica 2011; 96: 87-95.
16. Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, Rossi JF et al. Agonist antigp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000; 14: 188-197.
17. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 1998; 91: 4727-4737.
18. Zhang XG, Gu ZJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994; 179: 1337-1342.
19. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009; 114: 5173-5181.
20. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset FL. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 2002; 99: 2342-2350.
21. Frecha C, Fusil F, Cosset FL, Verhoeyen E. In vivo gene delivery into hCD34+ cells in a humanized mouse model. Methods Mol Biol 2011; 737: 367-390.
22. Caraux A, Perez-Andres M, Larroque M, Requirand G, Lu ZY, Kanouni T et al. Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection. Immunology 2011; 132: 266-272.
23. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079-1088.
24. Frecha C, Levy C, Costa C, Negre D, Amirache F, Buckland R et al. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol 2011; 85: 5975-5985.
25. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438.
26. Killmann SA, Cronkite EP, Fliedner TM, Bond VP. Cell proliferation in multiple myeloma studied with tritiated thymidine in vivo. Lab Invest 1962; 11: 845-853.
27. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A Study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008; 26: 4798-4805.
28. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692-1700.
29. Zhan F, Barlogie B, Mulligan G, Shaughnessy Jr JD, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008; 111: 968-969.
30. Di Bernardo A, Macor P, Guarnotta C, Franco G, Florena AM, Tedesco F et al. Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Expert Opin Biol Ther 2010; 10: 863-873.
31. Lu ZY, Condomines M, Tarte K, Nadal L, Delteil MC, Rossi JF et al. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol 2007; 35: 443-453.
32. Tarte K, Zhang XG, Legouffe E, Hertog C, Mehtali M, Rossi JF et al. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol 1999; 163: 514-524.
33. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KGC, Dorner T et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741-750.
34. Levy C, Frecha C, Costa C, Rachinel N, Salles G, Cosset FL et al. Lentiviral vectors and transduction of human cancer B cells. Blood 2010; 116: 498-500.